LePree’s job is to determine whether or not they can even move forward with the CNS drug and to build out a pipeline. “Weeks” away from clinical trials as of last cc. Ground Zero once again, but at least we have a little cash this time. Elite may go 2 years straight without submitting anything to FDA.
Also, Adderall ER is barely even scratching the surface of market share and has been decreasing. Not sure I’d be excited about another CNS product when expectations were at least 10% of the market, which is in a completely different ballpark.